NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

Exclusion criteria

• ✕2. Inhibitors of monoamine oxidase, UGT1A9, 1A10, and aldehyde or alcohol dehydrogenase should be discontinued 5 half-lives prior to active dose of psilocybin.
• ✕3. Eligible subjects will have a third-party transportation by a licensed driver (e.g. friend, family or a driver) after the psilocybin session is complete. If a driver is used, a friend or family member must accompany them in the vehicle home
• ✕4. Participants should agree to refrain from driving, operating heavy machinery, or engaging in safety-sensitive activities for the remainder of the day following psilocybin administration (for both 25mg or subperceptual 1mg placebo).
• ✕5. Fluent in English
• ✕. History of another primary malignancy, except for:
• ✕. Malignancy treated with curative intent and no active disease for ≥ 5 years before the first dose of study drug, with low potential risk for recurrence.
• ✕. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
• ✕. Adequately treated carcinoma in situ without evidence of disease.